ReviewEpigenomics2012
Epigenomics of idiopathic pulmonary fibrosis.
Review in Epigenomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Fibrotic interstitial lung diseases and air pollution: a systematic literature review.European respiratory review : an official journal of the European Respiratory Society · 2020Pooled it
- Identification of oxidative stress-related diagnostic markers and immune infiltration features for idiopathic pulmonary fibrosis by bibliometrics and bioinformatics.Frontiers in medicine · 2024Review
- Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis.Biotech (Basel (Switzerland)) · 2023Review
- Telomere Dysfunction in Idiopathic Pulmonary Fibrosis.Frontiers in medicine · 2021Review
- Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice.JCI insight · 2020Article
- Towards a global initiative for fibrosis treatment (GIFT).ERJ open research · 2017Article
- Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives.Canadian respiratory journal · 2017Review
- MicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeutics.Acta pharmaceutica Sinica. B · 2016Review
- Lung extracellular matrix and redox regulation.Redox biology · 2016Review
- Association of HLA and cytokine gene polymorphisms with idiopathic pulmonary fibrosis.The Kaohsiung journal of medical sciences · 2015Article
- Smoking and interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2015Review
- Review
- Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night.European respiratory review : an official journal of the European Respiratory Society · 2015Review
- Intratracheal Bleomycin Aerosolization: The Best Route of Administration for a Scalable and Homogeneous Pulmonary Fibrosis Rat Model?BioMed research international · 2015Article
- Genetic susceptibility and pulmonary fibrosis.Current opinion in pulmonary medicine · 2014Review
- The wound healing, chronic fibrosis, and cancer progression triad.Physiological genomics · 2014Review
- Integrating omics technologies to study pulmonary physiology and pathology at the systems level.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2014Review
- Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous.Clinical reviews in allergy & immunology · 2013Review
- Idiopathic pulmonary fibrosis: the need for early diagnosis.Multidisciplinary respiratory medicine · 2013Article
- Biomarkers in diabetic retinopathy and the therapeutic implications.Mediators of inflammation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Idiopathic pulmonary fibrosis (IPF) is a complex lung disease of unknown etiology. Development of IPF is influenced by both genetic and environmental factors. Gene-expression profiling studies have taught us quite a bit about the biology of this fatal disease, but epigenetic marks may be the missing link that connects the environmental exposure in genetically predisposed individuals to transcriptome changes associated with the development of IPF. This review will begin with an introduction to the disease, followed by brief summaries of studies of gene expression in IPF and epigenetic marks associated with exposures relevant to IPF. The majority of the discussion will focus on epigenetic studies conducted so far in IPF, the limitations, challenges nd future directions in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.